Chronic sleep restriction in rats induces metabolic dysfunction, increased plasma glucose, fasting insulin, lipids, insulin resistance and oxidative stress and decreases glucose tolerance; these parameters improve by treatment with piromelatine, a novel melatonin agonist, used for insomnia. Here, INS is linked to insomnia measurement.